VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
anti-VEGF agent
Approved
Small molecule
M
Medical University of Vienna
1
Indications
1
Total Trials
1
Active Trials
0
Competitors
Clinical
Trials by Indication
[1]
Intelligence
1 trial
Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
Recruiting
·
M
Medical University of Vienna
·
Phase 4
·
NCT05093374
·
290 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for anti-VEGF agent. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
anti-VEGF agent compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for anti-VEGF agent. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Medical University of Vienna company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Approved
[1]
Company
M
Medical University of Vienna
Related News